Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).

Publication ,  Journal Article
Pond, GR; Armstrong, AJ; Wood, BA; Brookes, M; Leopold, LH; Burke, JM; Caton, JR; Fleming, MT; Sonpavde, G
Published in: J Clin Oncol
March 2011

185 Background: Threeprognosticrisk groups have been identified in men with mCRPC (good [GR]/intermediate [IR]/poor [PR]) based on 0-1, 2 or 3-4 factors (visceral disease, pain, anemia, bone scan progression). Prostate Cancer Working Group (PCWG)-2 defines clinical subtypes with visceral disease, bone metastases ± nodal metastases and nodal disease only. The prognostic ability of risk grouping or PCWG2 subtypes was evaluated in a large, independent phase II trial. METHODS: A randomized phase IItrial of 221 men with mCRPC that received docetaxel-prednisone (DP) + AT-101 (Bcl-2 inhibitor) or DP + placebo was retrospectively analyzed using Cox regression and χ(2) tests. Additional outcomes, tests and measures of discriminatory ability were assessed and will be presented. Patients from both groups were combined for analysis, as no significant differences in outcomes were observed. RESULTS: 93, 81 and 38 men had GR, IR and PR disease. GR men were more likely than IR/PR men to be ECOG-PS 0 (48%, 27%, 21%) and had a lower median baseline PSA (63, 85, 193 ng/ml). Significant differences between risk groups were observed for progression-free survival (PFS, p=0.009) and overall survival (OS, p<0.001), while PCWG2 subtypes did not discriminate for these outcomes. Both risk groups and PCWG2 subtypes inconsistently predicted PSA declines (table). CONCLUSIONS: Prognostic risk groups significantly distinguished between outcomes in men with mCRPC receiving DP-based therapy, while PCWG2 subtypes did not. Risk groups may enhance stratification of patients in randomized trials and enable tailored drug development. Prognostic models that incorporate tumor molecular features may improve discriminatory ability. [Table: see text] [Table: see text].

Duke Scholars

Published In

J Clin Oncol

EISSN

1527-7755

Publication Date

March 2011

Volume

29

Issue

7_suppl

Start / End Page

185

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pond, G. R., Armstrong, A. J., Wood, B. A., Brookes, M., Leopold, L. H., Burke, J. M., … Sonpavde, G. (2011). Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol, 29(7_suppl), 185.
Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, J. M. Burke, J. R. Caton, M. T. Fleming, and G. Sonpavde. “Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).J Clin Oncol 29, no. 7_suppl (March 2011): 185.
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Burke JM, et al. Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2011 Mar;29(7_suppl):185.
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Burke JM, Caton JR, Fleming MT, Sonpavde G. Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2011 Mar;29(7_suppl):185.

Published In

J Clin Oncol

EISSN

1527-7755

Publication Date

March 2011

Volume

29

Issue

7_suppl

Start / End Page

185

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences